Extravasation: a dreaded complication of chemotherapy.
- [Show abstract] [Hide abstract]
ABSTRACT: Accidental extravasation of anthracycline-containing anticancer chemotherapy is a feared complication that may lead to progressive tissue damage. The condition may require extensive surgical intervention and often has severe long-term effects. Until a short while ago, there has been no effective treatment against the devastating effect of extravasated anthracycline. However, dexrazoxane has proven highly effective in preventing necrosis in both preclinical and clinical studies and is now approved in Europe (Savene), and has orphan drug status in the USA (Totect) for this indication. Hence, it is the first and only proven effective antidote against anthracycline extravasation injuries.Expert Review of Anti-infective Therapy 09/2007; 7(8):1081-8. · 2.07 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: A 75-year-old man diagnosed with lower esophageal adenocarcinoma suffered from epirubicin extravasation during the second cycle of neoadjuvant chemotherapy with epirubicin and oxaliplatin. A full recovery was achieved after treatment with dexrazoxane (Cardioxane® ). This is the first time in our hospital that extravasation of an anthracycline has been treated with dexrazoxane. We used Cardioxane® , approved for the prevention of anthracycline-induced cardiotoxicity, while Savene® is indicated for the treatment of anthracycline extravasation. The treatment was effective, and the selection of Cardioxane® (seven-fold cheaper than Savene® ) yielded a cost saving. Consequently, Cardioxane® has been included in our guidelines for anthracycline extravasation.Journal of cancer research and therapeutics 01/2010; 6(4):573-4. · 0.83 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Abstract This study aimed to compare the efficacy of topical dimethyl sulfoxide (DMSO), intralesional and systemic carnitine as monotherapy and in combination against ulceration in rats induced by intradermal doxorubicin extravasation. Sixty-nine 3-month-old male Wistar albino rats, weighing between 200-225 g, were used in this study. Rats were applied monotherapy or a combination of topical DMSO, intraperitoneal or intralesional carnitine. Control groups received saline or no drug. The necrotic area was measured and extravasated neutrophil leukocytes were counted in healthy tissue adjacent to necrotic areas. Monotherapy with topical and systemic carnitine did not significantly reduce the size of necrotic areas. However, topical DMSO had reduced necrotic areas and inflammatory cells significantly and the addition of systemic carnitine to topical DMSO had increased the efficacy. DMSO is an effective, safe, and easy-to-apply treatment for doxorubicin-induced extravasation. Further clinical studies are needed to evaluate the use of carnitine in combination with DMSO.Journal of plastic surgery and hand surgery. 05/2013;
Annals of Oncology 14 (Supplement 3): iii26–iii30, 2003
© 2003 European Society for Medical Oncology
Extravasation: a dreaded complication of chemotherapy
D. L. Schrijvers
Department of Medical Oncology, AZ Middelheim, Antwerp, Belgium
Most chemotherapeutic agents are given by intravenous adminis-
tration, although some drugs are available orally. When given
intravenously, these drugs cause few side-effects at the site of
injection. However, when they are injected or leak into the
surrounding tissues, a tissue reaction varying from irritation to
necrosis may arise.
In this article, a patient with extravasation is described and a
review of the literature is given.
A 69-year old woman was treated for a high-grade soft tissue
sarcoma of the leg by resection and radiotherapy. One year later,
she developed lymph node and lung metastases. Since her general
condition was excellent, a palliative chemotherapy with doxo-
rubicin was proposed. The patient agreed to the treatment and she
was admitted to the Department of Medical Oncology for her first
Doxorubicin at a dose of 75 mg/m2 was given by intravenous
injection. The nurse who had to administer the drug placed a but-
terfly needle in the right hand and injected the drug slowly. During
the injection, the patient did not complain of pain. After adminis-
tering the drug, the patient said she felt an excruciating pain in her
hand. The nurse removed the needle and called a physician. On
clinical examination, the woman had a slight redness of the right
hand without other signs. A local anti-inflammatory ointment was
applied to the hand and the patient was hospitalised.
The next day, she complained of pain and the hand was swollen
and red. A small ulceration had developed. The diagnosis of
extravasation was made and a local treatment with dimethyl-
sulfoxide (DMSO) was applied three times daily. The patient was
treated with analgesics. A surgeon was consulted who suggested
observation. After a week, necrosis of the skin developed with
exposure of the muscles and ligaments. The wound was treated
with sterile dressings. After 6 weeks a skin graft was placed over
A subcutaneous device was then put in place and doxorubicin
treatment continued. After two cycles, there was a partial response
and the patient was treated with six cycles of chemotherapy.
She sued the department for medical fault.
Extravasation is one of the most dreaded complications when
administering chemotherapy. It is defined either as the escape of a
chemotherapeutic agent from a vessel into the surrounding tissues
by leakage or as an involuntary injection of a drug into the tissues.
The frequency of extravasation in adults is considered to be between
0.1% and 6%.
The severity of tissue injury is dependent on the type and
concentration of the chemotherapeutic agent and the quantity
injected. Cytotoxic agents may be classified as irritants or vesi-
cants (Table 1).
Irritants are drugs that can cause an inflammatory reaction,
aching, swelling, pain or phlebitis at the injection site or along the
vein. They may cause sclerosis and hyperpigmentation along the
vein, burning, local warmth, discomfort, erythema or tenderness.
These symptoms are self-limiting and there are no long-term
Vesicants are drugs that may cause severe and lasting tissue
injury and necrosis. Symptoms may arise immediately after extra-
vasation or appear after several days or weeks. Patients may com-
plain of pain or local burning at the infusion site, mild erythema,
itching or swelling. Over time, the symptoms of erythema and
pain may increase and a discoloration and induration of the skin,
dry desquamation or blistering may develop. In case of a sig-
nificant extravasation, necrosis, eschar formation and ulceration
with involvement of underlying tissues may occur. The indolent
ulceration lacks granulation tissue formation and there is little
Prevention of extravasation
The most important approach to extravasation is prevention. Pre-
vention of extravasation takes into account several factors.
• In all departments where cytotoxic agents are given, written
guidelines for handling cytotoxic agents and procedures in case
of extravasation should be present. In addition to these guide-
lines, an extravasation kit, with all the necessary material and
drugs to treat extravasation, should be present . There should
also be a form to report the extravasation to the authorities (hos-
pital direction, legal department, nursing department).
• Persons responsible for administering cytotoxic drugs should
be informed and educated about the drugs and the problems they
may cause in case of extravasation and the procedures to follow
if this happens.
• A cytotoxic agent should not be administered in an extremity
if within the previous 48 h there was venopuncture above the
place of insertion of the catheter.
• For vesicant drugs, the placement of a subcutaneous device
before the start of chemotherapy is advisable; in case of
infusions of longer duration (e.g. more than 1-h infusions), the
placement of a subcutaneous device is obligatory.
by guest on July 12, 2011
• Drugs should never be administered using a butterfly needle,
and even in case of a bolus injection or a short infusion, a cath-
eter has to be inserted into a vein. Small and fragile veins should
be avoided. The catheter should never be inserted in a limb that
is affected by lymphoedema or has a neurological weakness.
Veins adjacent to tendons, nerves or arteries should be avoided,
while areas of high venous pressure should not be used.
• If the drugs are given by slow bolus injection by peripheral
infusion, the placement of the catheter should be in the forearm
and not in the hand. In case of extravasation, the tissues and
muscles in the forearm may prevent involvement of ligaments,
nerves and bone.
• Before administering a cytotoxic agent, the catheter is flushed
by a free flowing infusion with natrium chloride 0.9% or
glucose 5% solution for at least 5 min. At the end of the admin-
istration of a cytotoxic drug, the same procedure is repeated.
• The patient is informed that in case of pain or other discom-
fort the nurse should be informed immediately.
• The exact position of the catheter is checked by aspiration of
blood. The drug is then slowly injected. In case of complaints by
the patient, the administration is stopped, the nurse aspirates as
much as possible of the injected drug, stops the infusion, leaves
the catheter in place and calls for a physician .
• The physician gives instructions how to deal with the event
and may start treatment for extravasation. The event and the
treatment procedure should be noted in the patient file and on
the extravasation form.
Treatment of extravasation
The type of treatment for extravasation is dependent on the drug.
• In case of extravasation of an irritant, the catheter may be
removed and the affected extremity is elevated. Cold or warm
compresses may be applied. Hot packs are believed to cause
vasodilatation, leading to the dilution of the extravasated drug.
Cold packs may cause venous constriction leading to localiza-
tion of the drugs and therefore increase degradation of toxic
metabolites. They may also reduce local inflammation and pain.
• Inflammation may be treated with local anti-inflammatory
drugs. Pain should be treated by analgesics.
• In case of extravasation of a vesicant, the catheter is left in
place and an antidote may be injected depending on the extra-
vasated drug. Furthermore, the affected extremity is kept elevated
and a cold or hot pack is applied. In case of extravasation with
vinca alkaloids, a hot pack is applied, since in animal models
there was an increase in ulceration when cold packs were
applied. For all other vesicants cold packs are indicated.
Several drugs have been tested in the treatment of anthracycline
extravasation in animal models or patients.
Prevention of damage
Until recently, the application of topical DMSO has been advo-
cated for the treatment of extravasation of anthracyclines. Several
animal experiments [2, 3] and case reports have described the effi-
cacy of intradermal or topical DMSO .
In a prospective study, 17 patients were treated with topical
DMSO. It was applied immediately after extravasation covering
twice the area affected by the extravasation. This treatment was
repeated twice daily for 14 days. No ulceration developed and no
surgical intervention was necessary .
In another prospective study, 69 patients suffering from anthra-
cycline extravasation had 99% DMSO applied topically every 8 h
for 7 days in combination with intermittent cooling (1 h, three
times daily). This treatment proved to be safe and effective with
ulceration developing in only one patient. Side-effects were mild
local burning and a characteristic breath odor due to DMSO .
Recently, dexrazoxane has been advocated for the treatment of
anthracycline extravasation. In animal models, the use of one
single subcutaneous injection of dexrazoxane after an injection of
doxorubicin, daunorubicin or idarubicin reduced the tissue lesion
significantly, with a reduction in the size of the wound and the
healing duration. Dexrazoxane could be administered up to 3–6 h
after anthracycline extravasation without loss of efficacy. Triple
dosage of dexrazoxane appeared to be more effective than a single
Table 1. Vesicants and irritants
DNA-binding vesicant drugs
Alkylating agentsNitrogen mustard
AnthracyclinesDaunorubicin, doxorubicin, epirubicin, idarubicin
Others Dactinomycin, mitomycin C
Non-DNA-binding vesicant drugs
Vinca alkaloidsVinblastine, vincristine, vinorelbine
Alkylating agentsCarmustine, dacarbazine, carboplatin, cisplatin, cyclofosfamide,
ifosfamide, melphalan, oxaliplatin, thiothepa
AntimetabolitesCytarabine, fludarabine, 5-fluorouracil, gemcitabine, raltitrexed,
OthersIrinotecan, bleomycin, etoposide
by guest on July 12, 2011
This treatment was also tested in two patients with epirubicin
extravasation. Both patients were treated intravenously with
dexrazoxane (1000 mg/m2 within 5 h of extravasation on day 1,
1000 mg/m2 on day 2, 500 mg/m2 on day 3). No surgical interven-
tion was necessary and no long-term sequelae were seen after
3 months. The only side-effects were transient elevation of liver
transaminases and leukopenia .
Experimental animal studies have been performed with vitamin
C [3, 9], heparin fractions , hyaluronidase , N-acetyl-
cysteine  and α-tocopherol  showing a beneficial effect of
all these drugs in the prevention of anthracycline-induced ulcera-
tion. However, their value in patients remains to be determined.
Treatment of ulcerations
If injury occurs, the patient may develop ulceration with a raised,
red, painful edge and a necrotic yellow base. These ulcers lack
granulation tissue and there is very little peripheral epithelial
ingrowth. They do not heal and tend to increase in size and
In animal experiments, it was shown that the injection of
granulocyte–macrophage colony-stimulating factor (GM-CSF)
6 µg at the injection site of doxorubicin had a beneficial effect on
the doxorubicin-induced tissue necrosis . This beneficial
effect was confirmed in another animal model for granulocyte
colony-stimulating factor (G-CSF) or GM-CSF .
One patient has been reported who developed two doxorubicin-
induced ulcerations. One ulcer was treated with weekly GM-CSF
at a dose of 400 µg subcutaneously for 3 weeks and did heal by the
fourth week. The second ulcer was treated with G-CSF, but no
improvement was seen .
The use of hyperbaric oxygen therapy was also studied in
animal models. While hyperbaric oxygen treatment did potentiate
doxorubicin toxicity when administered concomitantly , it
had a beneficial effect on ulcer healing when given twice daily
compared with no hyperbaric treatment . To date, the value of
this approach in patients with ulcerations due to extravasation has
not been published.
In patients with ulcerations due to anthracycline extravasation,
two surgical approaches are possible. One surgical treatment option
is to perform early extensive surgical debridement within 24 h to
1 week after extravasation with delayed closure of the wound
[19, 20]. Pain is an indication for immediate surgery . The
extent of surgery may be determined by fluorescence microscopy.
Excision of all fluorescence-positive tissues led to less late
sequelae when performed within seven hours . The wound
may be temporarily covered with a biological dressing. Once the
wound is clean, a delayed application of a skin graft (split-thick-
ness) may be applied after 2–3 days .
Most surgeons opt for a conservative approach since only one-
third of vesicants will give rise to ulceration. However, continued
swelling, erythema and pain without ulceration, persisting after
conservative therapy or the presence of large areas of tissue necro-
sis or skin ulcerations are indications for surgery [23–26]. In this
case, surgery is usually performed 2–3 weeks after extravasation.
Mitomycin C is a vesicant . Contrary to anthracyclines,
distant and delayed ulcerations have been described [28–30]. As
for anthracyclines, toxicity of mitomycin C can be prevented by
the topical application of DMSO [31, 32]. Also, a topical mixture
of DMSO (90%) and α-tocopherol (10%) was effective in the
prevention of skin ulceration by mitomycin C . There is also a
report that local injection of pyridoxine may slow or prevent
necrosis and alleviate pain . In case of ulceration due to
extravasation, preoperative magnetic resonance imaging (MRI)
may be used to indicate the extent of tissue invasion .
Both docetaxel and paclitaxel have been reported to cause tissue
damage after extravasation. Several reports indicate that docetaxel
may cause erythema, blistering and pain. Conservative manage-
ment resulted in complete recovery after 4 weeks in one patient
, while the dilution with subcutaneous saline, local hypo-
thermia and topical DMSO (three times every 45 min), cortico-
steroids or diclofenac were effective in restricting inflammation
In animal models, paclitaxel gave rise to skin ulceration and
necrosis proving its vesicant character. A treatment with intra-
dermal hyaluronidase (15 U) diluted in saline was effective in
preventing paclitaxel-induced ulceration. Topical treatment as
topical DMSO, cooling or heating did not had a beneficial effect
Several case reports have reported on the vesicant character of
paclitaxel [40–43]. No guidelines for treating paclitaxel extra-
vasation in man have been proposed.
Vinblastine, vincristine and vinorelbine cause tissue damage after
extravasation and are classified as vesicants. Animal experiments
showed that cold packs may increase toxicity, while hot packs
may limit skin damage. Also, the use of calcium leucovorin,
diphenhydramine, hydrocortisone, isoproterenol, sodium bicar-
bonate and vitamin A cream were ineffective in animal models
In humans, dilution of the drugs with saline or hyaluronidase
(150–1500 U subcutaneously in surrounding tissues) in combin-
ation with hot packs is the treatment of choice [1, 44].
Nitrogen mustard or mechlorethamine
Nitrogen mustard is a vesicant that produces severe and prolonged
skin ulceration after extravasation. In several animal experiments,
sodium thiosulfate was not able to prevent nitrogen mustard skin
toxicity when given intravenously immediately before or after
extravasation. However, when given immediately after extra-
vasation by intradermal injection, it had a protective effect.
Therefore, in humans the recommendation in case of nitrogen
mustard extravasation is an immediate subcutaneous adminis-
by guest on July 12, 2011
tration of 2 ml of 0.17 M sodium thiosulfate solution (4 ml of 10%
sodium thiosulfate and 6 ml sterile water for injection) .
Extravasation is a severe complication of chemotherapy. Preven-
tion by adequate guidelines of chemotherapy administration and
training of nurses is of the utmost importance. In case of extra-
vasation, the correct treatment according to the specific drug
should be given (Table 2).
1. Pattison J. Managing cytotoxic extravasation. Nurs Times 2002: 98: 32–
2. Lebredo L, Barrie R, Woltering EA. DMSO protects against adriamycin-
induced tissue necrosis. J Surg Res 1992; 53: 62–65.
3. Hajaridadeh H, Lebredo L, Barrie R, Woltering EA. Protective effect of
doxorubicin in vitamin C or dimethyl sulfoxide skin ulceration in pig.
Ann Surg Oncol 1994; 1: 411–414.
4. Lawrence HJ, Walsh D, Zappotowski KA et al. Topical dimethyl sulf-
oxide may prevent tissue damage from anthracycline extravasation.
Cancer Chemother Pharmacol 1989; 23: 316–318.
5. Olver IN, Aisner J, Hament A et al. A prospective study of topical
dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol
1988; 6: 1732–1735.
6. Bertilli G, Gozza A, Forno GB et al. Topical dimethyl sulfoxide for the
prevention of soft tissue injury after extravasation of vesicant drugs: a pro-
spective clinical study. J Clin Oncol 1995; 13: 2851–2855.
7. Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extra-
vasation with dexrazoxane. Clin Cancer Res 2000; 6: 3680–3686.
8. Langer SW, Sehested M, Jansen PB et al. Dexrazoxane in anthracycline
extravasation. J Clin Oncol 2000: 18: 3064.
9. Yilmaz M, Demirdover C, Mola F. Treatment options in extravasation
injury: an experimental study in rats. Plast Reconstr Surg 2002; 109:
10. Askar I, Erbas MK, Gurlek A. Effects of heparin fractions on the preven-
tion of skin necrosis resulting from adriamycin extravasation; an experi-
mental study. Ann Plast Surg 2002; 49: 297–301.
11. Disa JJ, Chang RR, Mucci SJ, Goldberg NH. Prevention of adriamycin-
induced full thickness skin loss using hyaluronidase infiltration. Plast
Reconstr Surg 1998; 101: 370–374.
12. Schwartsmann G, Sander EB, Vinholes J et al. N-Acetylcysteine protects
skin lesion induced by local extravasation of doxorubicin in a rat model.
Am J Pediatr Hematol Oncol 1992; 14: 280–281.
13. Lucero MJ, Vigo J, Rabasco AM et al. Protection by α-tocopherol against
skin necrosis induced by doxorubicin hydrochloride. Pharmazie 1993; 48:
14. Eroglu E, Sari A, Altuntas I et al. The effect of GM-CSF (granulocyte
macrophage colony stimulating factor) on doxorubicin-induced tissue
necrosis and wound healing. Indian J Cancer 2000; 37: 153–157.
15. Vargel I, Erdem A, Ertoy D et al. Effects of growth factors on doxo-
rubicin-induced skin necrosis: documentation of histomorphological
alteration and early treatment by GM-CSF and G-CSF. Ann Plast Surg
2002; 49: 646–653.
16. Ulutin HC, Guden M, Dede M, Pak Y. Comparison of granulocyte-colony
stimulating factor and granulocyte macrophage-colony stimulating factor
in the treatment of chemotherapy extravasation ulcers. Eur J Gynaecol
Oncol 2000; 21: 613–615.
17. Monstrey SJ, Mullick P, Naranyanan K, Ramasastry SS. Hyperbaric
oxygen therapy and free radical production: a experimental study in doxo-
rubicin (adriamycin) extravasation injuries. Ann Plast Surg 1997; 38:
18. Aktas S, Toklu AS, Olgac V. Hyerbaric oxygen therapy in adriamycin
extravasation: a experimental animal study. Ann Plast Surg 2000; 45:
19. Heitmann C, Durmus C, Ingianni G. Surgical management after doxo-
rubicin and epirubicin extravasation. J Hand Surg 1998; 23: 666–668.
20. Hankin FM, Louis DS. Surgical management of doxorubicin (adria-
mycin) extravasation. J Pediatr Orthop 1984; 4: 96–99.
21. Larson DL. What is the appropriate management of tissue extravasation
by antitumor agents? Plast Reconstr Surg 1985; 75: 397–405.
22. Andersonn AP, Dahlstrom KK. Clinical results after doxorubicin extra-
vasation treated with excision guided by fluorescence microscopy. Eur J
Cancer 1993; 29A: 1712–1714.
23. Scuderi N, Onesti M. Antitumor agents: extravasation, management, and
surgical treatment. Ann Plast Surg 1994; 32: 39–44.
24. Tsavaris N, Komitsopoulou P, Karagiaouris P et al. Prevention of tissue
necrosis due to accidental extravasation of cytostatic drugs by a conser-
vative approach. Cancer Chemother Pharmacol 1992; 30: 330–333.
25. Heckler F. Current thoughts on extravasation injuries. Clin Plast Surg
1989; 16: 557–563.
Table 2. Guidelines for antidote use after extravasation
DMSO, dimethylsulfoxide; i.v., intravenously; s.c., subcutaneously.
AnthracyclinesDMSOApply locally as soon as possible and repeat
every 8 h for 7 days
Dexrazoxane1000 mg/m2 i.v. within 5 h of extravasation
on day 1, 1000 mg/m2 on day 2, 500 mg/m2 on day 3
Mitomycin CDMSOApply locally as soon as possible and repeat
every 8 h for 7 days
Nitrogen mustardSodium thiosulfate2 ml of a solution of 4 ml sodium thiosulfate
+ 6 ml sterile water for injection s.c.
Vinca alkaloidsHyaluronidase150–1500 U s.c.
by guest on July 12, 2011
26. Dorr R. Antidotes to vesicant chemotherapy extravasations. Blood Rev
1990; 4: 41–60.
27. Bikkers TH, Verweij J, van Geel AN, Stoter G. Severe tissue necrosis due
to extravasation of mitomycin. Ned Tijdschr Geneeskd 1987; 131: 588–590.
28. Patel JS, Krusa M. Distant and delayed mitomycin C extravasation. Phar-
macotherapy 1999; 19: 1002–1005.
29. Aizawa H, Tagami H. Delayed tissue necrosis due to mitomycin C. Acta
Derm Venereol 1987; 67: 364–366.
30. Murakami Y, Shibata S, Koso S et al. Delayed tissue necrosis associated
with mitomycin-C administration. J Dermatol 2000; 27: 413–415.
31. Bertelli G. Prevention and management of extravasation of cytotoxic
drugs. Drug Safety 1995; 12: 245–255.
32. Alberts DS, Dorr RT. Case report: topical DMSO for mitomycin C-
induced skin ulceration. Oncol Nurs Forum 1991; 18: 693–695.
33. Ludwig CU, Stoll HR, Obrist R, Obrecht JP. Prevention of cytotoxic
drug-induced skin ulcers with dimethyl sulfoxide and α-tocopherole. Eur
J Cancer Clin Oncol 1987; 23: 327–329.
34. Rentschler R, Wilbur D. Pyridoxine: a potential local antidote for Mito-
mycin-C extravasation. J Surg Oncol 1988; 37: 269–271.
35. Yama N, Tsuchida Y, Nuka S et al. Usefulness of magnetic resonance
imaging for surgical management of extravasation of an antitumor agent:
a case report. Jpn J Clin Oncol 2001; 31: 122–124.
36. Raley J, Geisler JP, Buekers TE, Sorosky JI. Docetaxel extravasation
causing significant delayed tissue injury. Gynecol Oncol 2000; 78: 259–
37. Berghammer P, Pohnl R, Baur M, Dittrich C. Docetaxel extravasation.
Support Care Cancer 2001; 9: 131–134.
38. Ascherman JA, Knowles SL, Attkiss K. Docetaxel (Taxotere) extravasa-
tion: a report of five cases with treatment recommendations. Ann Plast
Surg 2000; 45; 438–441.
39. Dorr RT, Snead K, Liddil JD. Skin ulceration potential of paclitaxel in a
mouse skin model in vivo. Cancer 1996; 78: 152–156.
40. Barutca S, Kadikoylu G, Bolaman Z et al. Extravasation of paclitaxel into
breast tissue from central catheter port. Support Care Cancer 2002; 10:
41. Herrington JD, Figueroa JA. Severe necrosis due to paclitaxel extravasa-
tion. Pharmacotherapy 1997; 17: 163–165.
42. Raymond E, Cartier S, Canuel C et al. Extravasation of paclitaxel (Taxol).
Rev Med Interne 1995; 16: 141–142.
43. Ajani JA, Dodd LG, Daughertyt K et al. Taxol-induced soft-tissue injury
secondary to extravasation: characterisation by histopathology and clin-
ical course. J Natl Cancer Inst 1994; 86: 51–53.
44. Dorr T. Antidotes to vesicant chemotherapy extravasation. Blood Rev
1990; 4: 41–60.
by guest on July 12, 2011